Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Loading news article.

Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol | WAPE

Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Article summary

Related companies

Comments —